Immuno-Oncology: A 360° View in NYC this February

Partner Content
Card image cap

The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° (IO360°) event is expanding to three days and will take place on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr Axel Hoos (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated.

“We are undergoing a radical change in cancer treatment and the biopharma industry needs to gain information that will be beneficial for industry and patients,” said Dr Hoos. “The conference will deal with a panoply of topics, including the investment landscape and key business deals, combination immunotherapies and how to test them in clinical trials, and what role the patient can have in clinical designs and recruitment procedures.”

The conference will feature keynote addresses on “Clonal Selection of Neo-Antigen Biology” led by Dr Sergio Quezada (University College London Cancer Institute); “Immune Checkpoint Blockade in Cancer Therapies: New Insights and Opportunities for Cures,” led by Dr James Allison (MD Anderson Cancer Center); and “A Melanoma Survivor Story: T.J. Sharpe’s Immunotherapy Trial Journey,” led by T.J. Sharpe (Melanoma Survivor, Advocate and Cancer Blogger). In addition to the keynotes, the conference has plenary sessions designed around:

  • Preclinical Science
  • Translational Science and New Technologies
  • Trends and Collaborations in the IO Space
  • Clinical Advancements Parts 1 and 2
  • Imaging Methodologies and Techniques for Immunotherapy
  • Business Aspects of Immuno-Oncology

IO360° is supported through partnerships with The Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), thePatient Empowerment Network (PEN) and the Society of Immunotherapy for Cancer (SITC).

“With the support of CRI, SITC, PEN and CIMT, the IO360° program will help drive the field of cancer immuno-therapy through knowledge sharing and disseminating the most current data, innovative approaches and developments that are changing the way cancer is treated,” said Kate Woda, Conference Director.

The speaking faculty at IO360° 2017 includes:

  • Maher Albitar, MD, SVP, Chief Medical Officer and Director of Research and Development, NeoGenomics Laboratories
  • James Allison, PhD, Chair, Department of Immunology, MD Anderson Cancer Center
  • Robert Ang, MD, MBA, Chief Business Officer, Neon Therapeutics
  • Kamran Ansari, Executive Director, Head of Oncology Clinical Sciences & Study Management GCTO, Merck
  • Roy Baynes, MD, PhD, SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories
  • Jeffrey Bockman, PhD, Vice President, Defined Health
  • Oliver Bohnsack, MD, PhD, MBA, Senior Director, Scientific and Medical Services, Head of Medical Relations Europe, Head of Oncology, Parexel Informatics Medical Imaging
  • Julie Brahmer, MD, Interim director / Director, Thoracic Oncology / Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
  • Brian Brown, PhD, Associate Professor, Icahn School of Medicine at Mount Sinai
  • Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString Technologies
  • Daniel Chen, MD, PhD, VP, Global Head of Cancer Immunotherapy Development, Genentech
  • Jonathan Cheng, MD, Executive Director, Oncology Clinical Development, Merck Research Laboratories
  • Peter Choyke, MD, FACR, Molecular Imaging Program Director / Senior Investigator / Head, Imaging Section, Center for Cancer Research, National Cancer Institute
  • Ashley Cornett, PhD, Technical Application Scientist, BioLegend
  • Charles Drake, MD, PhD, Director, Genitourinary Oncology / Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center
  • Noelle Gaskill, MBA, Senior Director, Research Operations, US Oncology Research
  • Lindee Goh, PhD, Partner, Tapestry Networks
  • James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
  • Priti Hegde, PhD, Anti-angiogenesis and Cancer Immunotherapy Franchises Biomarker Lead, Oncology Biomarkers, Genentech
  • Matthew Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center
  • Adi Hoess, MD, PhD, CEO, Affimed
  • Axel Hoos, MD, PhD, SVP, Oncology R&D, GlaxoSmithKline
  • Patrick Hwu, MD, Head, Division of Cancer Medicine / Department Chair, Melanoma Medical Oncology /Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center
  • Robert Iannone, MD, SVP, Head of Immuno-oncology, Global Medicines Development, AstraZeneca
  • Ramy Ibrahim, MD, VP and Head of R&D, Parker Institute for Cancer Immunotherapy
  • David Kaufman, MD, PhD, Executive Director, Translational Immuno-Oncology Lead, Oncology Clinical Research, Merck Research Labs
  • Patricia Keegan, MD, Director, Division of Oncology Products 2 (DOP2), OHOP, OND, CDER, FDA
  • Lanny Kirsch, MD, SVP, Translational Medicine, Adaptive Biotechnologies
  • Ron Korn, MD, PhD, Founder, Chairman and CMO, Imaging Endpoints
  • Jeffrey Legos, PhD, SVP, Oncology Global Development & Medical Affairs, Novartis Pharmaceuticals
  • Patrick Mayes, PhD, Director & Early Development Leader, GlaxoSmithKline
  • Adam Millinger, Founding Partner, ProMotion Career Management
  • Jill O’Donnell-Tormey, PhD, CEO and Director of Scientific Affairs, Cancer Research Institute
  • Michael O’Neal, MD, Chief Medical Officer, Head of Oncology, BioClinica
  • Andrea Perrone, MD, Head of Clinical Imaging, Translational Medicine, Merck Research Labs
  • Sergio Quezada, PhD, Head, Immune Regulation and Tumor Immunotherapy Group, University College London Cancer Institute
  • Chandra Ramanathan, PhD, MBA, VP and Head, East Coast Innovation Center, Bayer Healthcare
  • Eric Risser, Senior VP, Business Development & Portfolio Management, MacroGenics, Inc
  • Ryan Saadi, MD, MPH, Global Head, Market Access & Health Policy, Oncology Global Commercial Strategy Organization, Johnson and Johnson
  • Jeffrey Schlom, PhD, Chief, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute
  • Lawrence Schwartz, MD, Chief, Radiology Service, Columbia University Medical Center
  • Lesley Seymour, MD, PhD, Director IND Program & Compliance, Deputy Director / Professor, Oncology, Canadian Cancer Trials Group / Queens University
  • T.J. Sharpe, Melanoma Survivor, Advocate and Cancer Blogger
  • Roger Sidhu, MD, GPGM, Oncology Early Development, Amgen
  • Mark Simon, MBA, Partner, Torreya Partners
  • David Wholley, MPhil, Director, Research Partnerships Division, Foundation for the National Institutes of Health

About IO360
The Immuno-Oncology 360° program provides a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. IO360° is located at The Roosevelt Hotel, New York City, NY from February 1 - 3, 2017. For more information, visithere or go to

About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. The company examines and challenges the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. The company also presents PharmaTalkRadio with free podcasts for the life science industry and patient advocacy. For more information, visit

Grace Neary

10 January, 2017